Heat Biologics Shares Spiked Higher Midday, Now Up ~2%; Recent Zack’s Small Cap Research Report Suggested $19 Valuation Target On Stock
https://s27.q4cdn.com/906368049/files/News/2022/Zacks_SCR_Research_01132022_HTBX_Vandermosten.pdf
Heat Biologics Issues New PTX-35 Preclinical Data In Organ Transplantation, Update On HS-110
Heat Biologics Inc (NASDAQ: HTBX) announced
Heat Biologics Announces New PTX-35 Preclinical Data In Organ Transplantation And Provides Update On HS-110
A single dose of the preclinical version of PTX-35 (mPTX-35), was able to expand regulatory T cells (Tregs) and significantly improve disease and graft survival outcomes.
Chemically induced pancreatic failure (a model
Heat Biologics To Bolster Presence In Biodefense Space With Elusys Acquisition
Heat Biologics Inc (NASDAQ: HTBX)
Heat Biologics Files For U.S. Patent Titled ‘IMMUNE-MEDIATED CORONAVIRUS TREATMENTS’
https://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.html&r=1&f=G&l=50&d=PG01&p=1&S1=20210283242&OS=20210283242&RS=20210283242
HTBX: September Business Update
By John Vandermosten, CFA
NASDAQ:HTBX
READ THE FULL HTBX RESEARCH REPORT
Heat Biologics Is Starting To Run Away From Support Toward Resistance
Heat Biologics Inc. (NASDAQ: HTBX) shares traded higher Thursday morning after the company announced the launch of its wholly-owned subsidiary Skunkworx Bio Inc. focused on developing a drug discovery paradigm to enable rapid drug deployment.
Heat Biologics Announces Launch Of Its Skunkworx Bio Subsidiary
Heat Biologics, Inc. ("Heat") (NASDAQ: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, today announced the launch